CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
This is the first update to the original CTS communication distributed on July 6th. As previously co...
CTS Tampa has implemented the Ortho Vitros Anti-SARS-CoV-2 Total test which qualitatively detects an...
The CTS forms listed below have been revised with an implementation date of September 2, 2019. ...
On September 23, 2019, the new CTS Laboratory Information System successfully implemented in Da...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
Celebrate National Blood Donor Month throughout January by inviting eligible individuals to donate b...